The biotech game isn’t for the faint of heart. It’s for those who navigate molecular warfare and still make it to Monday with a war chest and a clinical milestone. Therini Bio, Inc. just raised a $39M Series A extension, not to make noise, but to silence the chaos inside your brain and retina. With this round, they’ve officially stacked $75M in Series A funding and $101.66M in total capital. Translation? They’re not here for the scenery but to rewire how we treat neuroinflammation at its vascular root.
Therini didn’t wander into this. This is decades of sharp-focus science, spun out from Dr. Katerina Akassoglou at Gladstone Institutes, where she uncovered fibrin as the smoke signal for neuroinflammation. Fast forward to 2025: she’s Scientific Founder, and Therini is headquartered in Sacramento, evolved from its MedaRed days in South SF. They're not repackaging tired theories. They’re going after the fibrin monster, a toxic protein that sneaks through compromised blood vessels and sets your immune system off like it just drank gasoline.
Their weapon? THN391, a high-affinity monoclona antibody that targets the inflammatory epitope on fibrin. It’s threading a needle in a hurricane, shutting down neuroinflammation without touching coagulation. Phase 1a? Done. Safe, clean, and prepped for monthly dosing. Phase 1b in Alzheimer’s and DiabeticMacularEdema? Locked and loaded for 2025. They’re not chasing symptoms. They’re cutting power to the whole damn fire.
Credit where it’s due: CEO Dr. Tara Nickerson has the reins, bringing decades of biopharma strategy from Maze and Prothena. Exec. Chair Frank Lee, formerly of Forma (picked up by Novo Nordisk for $1.1B), is the quiet force turning promise into global playbooks. And Dr. Aaron Kantor leads translational sciences like a man who’s been in the trenches for 30 years, and has the battle scars to prove it.
The investor list reads like the who’s who of strategic biotech capital. Angelini Ventures and Apollo Health Ventures join returning believers like SV Health Investors, MRL Ventures Fund LLC (Merck), Sanofi Ventures, Eli Lilly and Company, and Dolby Family Ventures. If you’re wondering whether pharma is watching closely, they’re not watching, they’re betting.
And Therini is also cooking a fibrin / VEGF bispecific antibody, think of it as their next chess move in retinal disease. The IP? Locked down. The roadmap? Precision-plotted. The goal? Change the conversation in Alzheimer’s and DME, and maybe even MS and TBI while they’re at it.
They named the company Therini. Not by accident. This isn’t just therapy, it’s therapy that slices through inflammation with surgical purpose. Watch this space. They’re just getting warmed up.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
If engineering peace of mind is what you crave, Vention is your zen.